Home » Despite Short-Term Costs, Guidant Acquisition Seen as Boon to Abbott
Despite Short-Term Costs, Guidant Acquisition Seen as Boon to Abbott
July 21, 2006
Analysts are projecting a sunny outlook for Abbott Laboratories based on 2006 second-quarter results — despite some company challenges.
At first glance, the company may seem to be faring worse than it actually is, said stock market website www.SeekingAlpha.com Editor Jonathan Liss.